Abstract:
New therapeutic strategies are needed for pediatric acute myeloid leukemia to reduce disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric patients with newly diagnosed acute myeloid leukemia. AAML1031 randomized patients younger than 30 years of age with de novo acute myeloid leukemia to standard treatment with or without bortezomib. All patients received the identical chemotherapy backbone with either four intensive chemotherapy courses or three courses followed by allogeneic hematopoietic stem cell transplantation for high-risk patients. For those randomized to the intervention arm, bortezomib 1.3 mg/m2 was given on days 1, 4 and 8 of each chemotherapy course. For those randomized to the control arm, bortezomib was not administered. In total, 1097 patients were randomized to standard chemotherapy (n=542) or standard chemotherapy with bortezomib (n=555). Remission induction rate did not differ between bortezomib and control treatment arms (89% vs 91%, p=0.531). Bortezomib failed to improve three-year event-free survival (44.8±4.5% vs 47.0±4.5%, p=0.236) or overall survival (63.6±4.5 vs 67.2±4.3, p=0.356) compared with the control arm. However, bortezomib was associated with significantly more peripheral neuropathy (p=0.006), and intensive care unit admissions (p=0.025) during the first course. The addition of bortezomib to standard chemotherapy increased toxicity but did not improve survival.
These data do not support the addition of bortezomib to standard chemotherapy in children with de novo acute myeloid leukemia. (NCT01371981; https://www.cancer.gov/clinicaltrials/NCT01371981).
Introduction:
Pediatric acute myeloid leukemia (AML) is the second most common pediatric leukemia and requires intensive therapy for cure.(1, 2) Despite the intensity of AML chemotherapy, which includes a very high cumulative lifetime anthracycline exposure in patients treated with chemotherapy alone or allogeneic donor stem cell transplantation in first remission, approximately 50% of patients will experience disease recurrence. (3, 4) Moreover, treatment-related mortality limits the ability to further intensify therapy. (5) Thus, new therapies are needed to improve the outcomes of children with AML.
The development and evaluation of targeted therapies for children with AML is the highest clinical research priority for the Myeloid Committee in the Children's Oncology Group (COG). (6) After successfully demonstrating an improvement in event free survival (EFS) in children treated with gemtuzumab, (3, 4) COG sought to evaluate the efficacy of bortezomib, a first generation proteasome inhibitor approved for multiple myeloma and non-Hodgkin lymphoma. Bortezomib was selected based on preliminary data demonstrating that AML have increased proteasomes and are more sensitive to proteasome inhibitor-mediated apoptosis,(7) AML stem cells have increased NF-κB that is selectively targeted with proteasome inhibitors, (8) (9) (10) (11) preclinical data from the pediatric preclinical testing program showing activity against leukemia cell lines, (12, 13) and studies in adults with AML demonstrating clinical benefit. (14) (15) (16) At the time of AAML1031 study opening, a COG pediatric Phase I single agent bortezomib trial had determined the single agent maximum tolerated dose, (17) and Phase II trial (AAML07P1) combining bortezomib with AML chemotherapy for patients with relapsed AML was nearing completion. (18) Since the available safety and efficacy data for combining bortezomib with standard AML chemotherapy was limited, COG, in collaboration with the Cancer Therapy Evaluation Program (CTEP) designed AAML1031 as a definitive efficacy Phase III trial with an interim toxicity analysis to ensure that combining bortezomib with standard AML chemotherapy was safe. The primary objective of AAML1031 was to assess definitively the impact of bortezomib in combination with standard AML chemotherapy on EFS for children with newly diagnosed AML without high allelic ratio (HAR) FLT3 ITD. A second objective was to evaluate the impact of bortezomib on overall survival (OS). Based on the available preliminary data at the time of study initiation, bortezomib was hypothesized to improve both EFS and OS. Multiple secondary objectives included an expanded safety assessment, multiple biology correlative studies, and secondary clinical data analyses.
Methods:
AAML1031 was an open-label multi-center randomized trial including patients aged 0 to 29.5 years with previously untreated primary AML. Exclusion criteria were prior chemotherapy, acute promyelocytic leukemia [t(15;17)], juvenile myelomonocytic leukemia, bone marrow failure syndromes, or secondary AML. The National Cancer Institute's central institutional review board (IRB) and IRBs at each enrolling center approved the study; patients and families provided informed consent or assent as appropriate. The trial was conducted in accordance with the Declaration of Helsinki. The trial was registered at www.clinicaltrials.gov as NCT01371981.
Patients were randomly assigned at enrollment to either standard AML treatment or standard treatment with bortezomib. Randomization was conducted in blocks of 4.
Bortezomib was administered at a dose of 1.3 mg/m 2 once on days 1, 4, and 8 of each chemotherapy course.
Patients with high allelic ratio FLT3 ITD were offered enrollment in a Phase I sorafenib treatment arm if that arm was open. Patients with HAR FLT3 ITD who declined enrollment in the sorafenib arm or who enrolled while the arm was suspended continued to receive treatment according to their initial randomization. These patients were included in safety analyses but were excluded from all efficacy analyses.
Patients were classified as low or high risk after Induction I. Low risk patients received four courses of chemotherapy and high risk patients received three courses of chemotherapy followed by allogeneic SCT. High risk patients without an appropriate donor received four courses of chemotherapy.
The primary endpoint was EFS from study entry. EFS was defined as the time from study entry until death, refractory disease, or relapse of any type, whichever occurred first. The secondary endpoints were OS, remission rates, relapse risk, post induction disease free survival (DFS), and treatment-related mortality (TRM). OS was defined as time from study entry until death. Relapse risk was defined as the time from the end of Induction II for patients in complete remission (CR) to relapse, where deaths without a relapse were considered competing events. DFS was defined as the time from end of Induction II for patients in CR until relapse or death. Refractory disease was defined as the persistence of CNS disease after Induction I, or the presence of morphologic bone marrow blasts ≥ 5% or any extramedullary disease at the end of Induction II. Patients with refractory disease were removed from protocol therapy. TRM was defined as the time from either study entry, or from end of Induction II for patients in CR, to deaths without a relapse with relapses considered as competing events. Patients without an event were censored at their date of last known contact. However for TRM analyses, patients were censored 30 days post end of therapy or 200 days post SCT.
Statistical Analysis: The study was designed with 1-sided testing and 2.5% type I error rate and 80% power to detect a 9% difference in EFS plateaus (52% vs. 61%, hazard ratio = 0.78) between patients without HAR FLT3 ITD randomized to standard therapy versus bortezomib/standard combination therapy. All p values are two-sided. Please see supplemental data for additional methods.
Results:
Between February 2011 and January 2016, AAML1031 enrolled 1,231 patients, ages 0 to 29.5 years, who had previously untreated primary AML at 184 institutions. Data for this analysis were frozen December 31, 2017, with a median follow-up period of 3.0 years (range, 0 to 6.0 years) for patients alive at last contact. After 132 patients were excluded (32 patient not meeting eligibility criteria, 102 patients with HAR FLT3 ITD who either enrolled, n=60, or did not enroll, n=42, on the Phase I sorafenib treatment arm that concluded enrollment on July 31, 2017), 1,097 patients were eligible for analysis. Figure 1 illustrates the reasons for exclusion and that 555 participants were randomized to the bortezomib arm and 542 to the control arm.
Accrual to the main randomization completed on January 15, 2016. As of March 14, 2016, the projected relapse event horizon was reached and outcome analyses indicated that the addition of bortezomib did not improve EFS, DFS or OS but did demonstrate a higher incidence of non-fatal treatment related toxicities. Therefore institutions were notified on this date that patients receiving protocol therapy on the bortezomib arm should switch to the standard chemotherapy arm immediately. There were 22 patients who were receiving protocol therapy on the bortezomib arm at this time. Of the 1097 patients enrolling on AAML1031, approximately 84% survived and achieved a remission at the end of two courses of induction. For the 1024 patients who initiated the second course of induction therapy and were evaluable at the end of Induction II, the remission rate was 90% and did not differ by study arm. As shown in Figure 2 and in Table 3 ) and by age category (Supplemental Table 4 ) did not
show any evidence for subtype or age specific bortezomib responses.
Univariable and multivariable Cox analyses from study entry and end of Induction II are shown in Table 3 and Supplemental Table 5 . Initial white blood cell count (WBC) greater than 100,000 was significantly associated with an increased risk of relapse, treatment related mortality, and decreased survival from study entry. Age greater or equal to 11 years old was associated with a decreased risk of relapse and increased survival. Black race, a previously observed risk factor, (3, 19) was no longer a significant risk factor for relapse or death. The magnitude and significance of these associations remained stable between univariate and multivariable analyses.
Interim analyses of treatment related mortality and ARDS after 100 patients were randomized to bortezomib did not cross predefined toxicity thresholds. Overall treatment related mortality, and targeted toxicity data are shown in Table 4 and Supplemental   Table 6 . No differences were observed in overall or course specific TRM. While most toxicity rates did not differ by treatment arm, peripheral neuropathy, dose reductions, and PICU admissions were consistently increased in patients receiving bortezomib in combination with standard chemotherapy. Course specific increased rates of ARDS and hypoxia were observed in the patients treated with bortezomib with standard chemotherapy. However, the reported rates of these toxicities was relatively low and did not differ from rates in patients treated with standard chemotherapy alone. No differences in infectious complications, renal toxicities, or decline in shortening fraction/ejection fraction were observed between treatment arms (Supplemental Table   7 ). Subgroup toxicity analyses by patient age demonstrated increased toxicities in Arm B patients with increasing age (Supplemental Table 8 ) amongst patients who completed all four courses of chemotherapy.
Discussion:
The AAML1031 trial data demonstrate that the addition of bortezomib to standard chemotherapy does not improve EFS or OS. However, bortezomib caused additional treatment related toxicity, specifically peripheral neuropathy, dose reductions and PICU admissions. Given the lack of clinical benefit and increased toxicity observed in the bortezomib treatment arm, bortezomib was discontinued in all patients who remained on protocol mandated therapy. While the preliminary data regarding bortezomib efficacy in adults with AML was promising, (14) (15) (16) In conclusion, the AAML1031 trial demonstrates that bortezomib can be combined safely with standard pediatric AML chemotherapy but that this combination does not improve EFS or OS and is associated with increased toxicity. Thus, these data do not support the use of bortezomib in pediatric AML therapy at this time. Despite this, the successful conduct of this very complex trial highlights the clinical trial capabilities of COG in partnership with CTEP and may serve as a paradigm for definitive efficacy clinical trials initiated in the setting of limited preliminary data. Finally, the AAML1031 clinical trial data set, in conjunction with ongoing biology studies, will serve as an invaluable data platform for future clinical and translational investigations.
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Methods:
This was an open-label multi-center randomized trial conducted by COG in the United Patients were randomly assigned at enrollment to either standard AML treatment or standard treatment with bortezomib given in each chemotherapy course. The allocation sequence was computer generated and randomization was conducted in blocks of 4.
States
For those allocated to the intervention arm, bortezomib was given at a dose 1.3 mg/m 2 administered once on days 1, 4, and 8 of each chemotherapy course.
Patients were classified as low or high risk after Induction I (defined below). Low risk patients received four courses of chemotherapy. Patients classified as high risk received three courses of chemotherapy followed by allogeneic SCT. Choice of alternative donors were at the transplantation center's discretion and included matched or 1-antigen mismatched unrelated donors, 4-to-6 antigen matched cord blood, or mismatched family donor with at least one haplotype match or 5-of-6 antigen phenotypic match. High risk patients without an appropriate donor received four courses of chemotherapy. Supplemental table 9 presents protocol mandated chemotherapy courses and doses.
Targeted toxicity monitoring for infectious and other toxicities was employed as previously described.
(1) In addition, an echocardiogram was mandated prior to each course of protocol therapy and values for the lowest shortening fraction and ejection fraction in each course were submitted by treating centers.
Patients were classified as either low risk or high risk based on diagnostic cytogenetic and molecular risk features and disease response after Induction I. Low risk was defined by the presence of t(8;21)(q22;q22), inv(16)(p13.1q22), or t(16;16)(p13.1;q22), NPM, or CEBPA mutations. Low risk was also defined by negative minimal residual
